Opinicus Capital Inc. Raises Holdings in Eli Lilly and Company $LLY

Opinicus Capital Inc. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 3,596 shares of the company’s stock after acquiring an additional 101 shares during the period. Eli Lilly and Company comprises about 2.1% of Opinicus Capital Inc.’s holdings, making the stock its 10th largest position. Opinicus Capital Inc.’s holdings in Eli Lilly and Company were worth $2,803,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the first quarter valued at approximately $27,000. Blume Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth approximately $35,000. TD Capital Management LLC boosted its holdings in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the period. Finally, Family CFO Inc purchased a new stake in Eli Lilly and Company in the 2nd quarter worth $54,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on LLY shares. UBS Group increased their price objective on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a report on Friday, November 7th. HSBC upped their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Guggenheim restated a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Berenberg Bank reissued a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $999.28.

Eli Lilly and Company Trading Up 0.2%

Shares of NYSE LLY opened at $1,024.67 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,033.62. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $968.70 billion, a price-to-earnings ratio of 66.97, a PEG ratio of 1.21 and a beta of 0.43. The business’s 50 day moving average price is $826.89 and its 200-day moving average price is $780.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the company posted $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.